MedPath

Rifampicin

Generic Name
Rifampicin
Brand Names
Isonarif, Rifadin, Rifamate, Rifater, Rofact
Drug Type
Small Molecule
Chemical Formula
C43H58N4O12
CAS Number
13292-46-1
Unique Ingredient Identifier
VJT6J7R4TR
Background

A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication

Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions
Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
Associated Therapies
Antibacterial therapy
Clinical Trials
Related News

Prediction of Drug Interactions With CYP2C9 Substrates

Not Applicable
Completed
Conditions
Healthy Volunteers
First Posted Date
2005-09-27
Last Posted Date
2008-10-29
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
16
Registration Number
NCT00226538
Locations
🇮🇱

Hadassah Medical Organization, Jerusalem, Israel

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

Phase 1
Completed
Conditions
Neoplasms
Advanced Solid Tumors
Interventions
First Posted Date
2005-09-21
Last Posted Date
2020-11-02
Lead Sponsor
R-Pharm
Target Recruit Count
19
Registration Number
NCT00207090
Locations
🇺🇸

The Cleveland Clinic Foundation, Cleveland, Ohio, United States

Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)

Phase 3
Completed
Conditions
Latent Tuberculosis Infection
Interventions
First Posted Date
2005-09-15
Last Posted Date
2017-12-19
Lead Sponsor
McGill University
Target Recruit Count
844
Registration Number
NCT00170209
Locations
🇧🇷

Universidade Gama Filho, Centro de Ciências Biológicas e da Saúde, Rio de Janeiro, Brazil

🇮🇩

Health Research Unit, Faculty of Medicine, Bandung, West Java, Indonesia

🇧🇯

Centre de Pneumophthysiologie, Cotonou, Benin

and more 6 locations

Tuberculosis Treatment Shortening Trial

Phase 3
Completed
Conditions
Tuberculosis
Interventions
First Posted Date
2005-08-15
Last Posted Date
2018-11-08
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
394
Registration Number
NCT00130247
Locations
🇧🇷

Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória, Espírito Santo, Brazil

🇺🇬

Mulago Hospital Complex, Kampala, Uganda

🇵🇭

Makati Medical Center, Makati, National Capital Region, Philippines

Treatment of Latent TB Infection for Jailed Persons

Phase 3
Completed
Conditions
Tuberculosis
Interventions
First Posted Date
2005-08-09
Last Posted Date
2020-07-21
Lead Sponsor
University of California, San Francisco
Target Recruit Count
364
Registration Number
NCT00128206
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness

Phase 2
Completed
Conditions
Onchocerciasis
First Posted Date
2005-08-08
Last Posted Date
2024-08-15
Lead Sponsor
Centers for Disease Control and Prevention
Target Recruit Count
80
Registration Number
NCT00127504
Locations
🇬🇹

Universidad del Valle/MERTU, Guatemala City, Guatemala

Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults

Not Applicable
Completed
Conditions
HIV Infections
Tuberculosis
Interventions
First Posted Date
2004-11-17
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
18
Registration Number
NCT00096850
Locations
🇺🇸

Vanderbilt Therapeutics CRS, Nashville, Tennessee, United States

🇺🇸

The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States

🇺🇸

Stanford CRS, Palo Alto, California, United States

Tuberculosis Prevention for HIV Infected Adults

Phase 3
Completed
Conditions
HIV Infections
Tuberculosis
Interventions
First Posted Date
2003-03-28
Last Posted Date
2012-10-22
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
1148
Registration Number
NCT00057122
Locations
🇿🇦

Chris Hani Baragwanath Hospital, Soweto, South Africa

Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis

Phase 2
Completed
Conditions
Multiple Sclerosis
First Posted Date
2002-08-08
Last Posted Date
2005-06-24
Lead Sponsor
National Center for Research Resources (NCRR)
Target Recruit Count
40
Registration Number
NCT00043264
Locations
🇺🇸

University of Texas Medical School, Houston, Texas, United States

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed
Conditions
HIV Infections
Interventions
Drug: darunavir/ritonavir dosage #1
Drug: TAF w/cobicistat
Drug: elvitegravir/cobicistat
Drug: darunavir/cobicistat
Drug: atazanavir/cobicistat
Drug: lopinavir/ritonavir dosage #1
Drug: atazanavir/ritonavir/tenofovir dosage #1
Drug: lopinavir/ritonavir dosage #2
Drug: indinavir/ritonavir dosage #1
Drug: atazanavir/ritonavir dosage #1
Drug: tipranavir/ritonavir
Drug: darunavir/ritonavir dosage #4
Drug: indinavir/ritonavir dosage #2
Drug: darunavir/ritonavir dosage #2
Drug: lopinavir/ritonavir dosage #3
Drug: lopinavir/ritonavir dosage #4
Drug: tenofovir/atazanavir/ritonavir dosage #2
Drug: atazanavir/ritonavir dosage #2
Drug: darunavir/ritonavir dosage #3
Drug: levoflaxacin
Drug: ethionamide/prothionamide
Drug: terizidone/cycloserine
Drug: para-aminosalicylic acid (PAS)
First Posted Date
2002-08-01
Last Posted Date
2022-07-22
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
1578
Registration Number
NCT00042289
Locations
🇺🇸

Usc La Nichd Crs, Los Angeles, California, United States

🇿🇦

Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa

🇺🇸

Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States

and more 59 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy